{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:39:25Z","timestamp":1793165965383,"version":"4.5.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Study Design<\/jats:title><jats:p>A systematic review and Meta-analysis<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary of Background Data<\/jats:title><jats:p>While bisphosphonates have historically been the cornerstone of pharmacological management for bone protection in patients, emerging evidence suggests that teriparatide and denosumab warrant further investigation as potential first-line treatments. The optimal choice among denosumab, teriparatide, and oral bisphosphonates for the treatment of postmenopausal osteoporosis remains a subject of ongoing debate and controversy within the scientific community.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This systematic review adhered meticulously to the rigorous standards outlined by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines as well as the Cochrane Collaboration recommendations. Additionally, it employed the AMSTAR (Assessing the methodological quality of systematic reviews) criteria to ensure methodological robustness and enhance the credibility of the findings. A systematic electronic search was conducted across Web of Science, PubMed, and the Cochrane Library databases from their inception dates up to February 2024.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In this meta-analysis of studies, our findings suggest that compared to bisphosphonates, both teriparatide and denosumab demonstrated notable increases in percentage changes in lumbar spine bone mineral density (BMD) among postmenopausal osteoporosis patients. Furthermore, denosumab exhibited superiority over teriparatide and oral bisphosphonates in enhancing percentage changes in both femoral neck and total hip BMD, indicating its potential as a more efficacious option. Regarding safety outcomes, no significant differences were observed in the incidence of serious adverse events among patients treated with teriparatide, denosumab, and bisphosphonates. However, teriparatide showed superiority over oral bisphosphonates in terms of a lower risk of general adverse events, suggesting a favorable safety profile.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, our study suggests that teriparatide and denosumab demonstrate comparable or potentially superior efficacy and safety profiles compared to oral bisphosphonates for the treatment of postmenopausal osteoporosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>PROSPERO, identifier CRD42024508382.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1431676","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T04:39:07Z","timestamp":1725251947000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Jia","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongning","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huikang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Nan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7326\/m15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: A clinical practice guideline update from the american college of physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0749-0690(02)00022-8","article-title":"Osteoporosis in elderly: prevention and treatment","volume":"18","author":"Srivastava","year":"2002","journal-title":"Clin Geriatr Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s13018-023-03920-4","article-title":"Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: A systematic review and meta-analysis","volume":"18","author":"Yuan","year":"2023","journal-title":"J Orthop Surg Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2021036","article-title":"Menopausal osteoporosis: screening, prevention and treatment","volume":"62","author":"Yong","year":"2021","journal-title":"Singapore Med J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2021.301","article-title":"Long-term treatment of postmenopausal osteoporosis","volume":"36","author":"Brown","year":"2021","journal-title":"Endocrinol Metab (Seoul Korea)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijsu.2019.03.004","article-title":"Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis","volume":"66","author":"Yuan","year":"2019","journal-title":"Int J Surg (London England)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-022-02272-z","article-title":"Novel formulations of oral bisphosphonates in the treatment of osteoporosis","volume":"34","author":"Fuggle","year":"2022","journal-title":"Aging Clin Exp Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13075-021-02446-6","article-title":"Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: A systematic review from 2000 to 2020","volume":"23","author":"Fern\u00e1ndez-Mart\u00edn","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4175-0","article-title":"Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis","volume":"28","author":"Saito","year":"2017","journal-title":"Osteoporosis international: J established as result cooperation between Eur Foundation Osteoporosis Natl Osteoporosis Foundation USA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0525-7","article-title":"Denosumab: A review in postmenopausal osteoporosis","volume":"35","author":"Deeks","year":"2018","journal-title":"Drugs Aging"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.860133","article-title":"Denosumab in osteoporosis","volume":"13","author":"Diab","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x18805759","article-title":"New and emerging concepts in the use of denosumab for the treatment of osteoporosis","volume":"10","author":"Lewiecki","year":"2018","journal-title":"Ther Adv musculoskeletal Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071403","article-title":"Review of current real-world experience with teriparatide as treatment of osteoporosis in different patient groups","volume":"10","author":"Hauser","year":"2021","journal-title":"J Clin Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(04)90128-2","article-title":"Teriparatide: A review","volume":"26","author":"Quattrocchi","year":"2004","journal-title":"Clin Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (Prisma-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7326\/m14-2385","article-title":"The prisma extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","article-title":"The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/08968608221146867","article-title":"Differences in prevalence of reduced and low bone mineral density between lumbar spine and femoral neck in peritoneal dialysis patients using dual-energy X-ray absorptiometry (Dxa)","volume":"43","author":"Davenport","year":"2023","journal-title":"Peritoneal Dialysis international: J Int Soc Peritoneal Dialysis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00744-w","article-title":"Effects of different types of exercise on bone mineral density in postmenopausal women: A systematic review and meta-analysis","volume":"107","author":"Kemmler","year":"2020","journal-title":"Calcif Tissue Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: A meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J\u00a0Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-069722","article-title":"Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis","volume":"378","author":"Pereira","year":"2022","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2020.9001","article-title":"Biportal endoscopic decompression vs. Microscopic decompression for lumbar canal stenosis: A systematic review and meta-analysis","volume":"20","author":"Chen","year":"2020","journal-title":"Exp Ther Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.Ed000142","article-title":"Updated guidance for trusted systematic reviews: A new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","article-title":"Bugsnet: an R package to facilitate the conduct and reporting of bayesian network meta-analyses","volume":"19","author":"B\u00e9liveau","year":"2019","journal-title":"BMC Med Res Method"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res synthesis Methods"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116416","article-title":"Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: the terabit study","volume":"160","author":"Chiba","year":"2022","journal-title":"Bone"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-019-0561-x","article-title":"Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate vero clinical trial","volume":"14","author":"Minisola","year":"2019","journal-title":"Arch Osteoporos"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (Vero): A multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the vero trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: A randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporosis international: J established as result cooperation between Eur Foundation Osteoporosis Natl Osteoporosis Foundation USA"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the daps (Denosumab adherence preference satisfaction) study: A 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporosis international: J established as result cooperation between Eur Foundation Osteoporosis Natl Osteoporosis Foundation USA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.12659\/msm.881905","article-title":"Teriparatide vs. Alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, bmd and quality of life","volume":"17","author":"Panico","year":"2011","journal-title":"Med Sci Monit"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1378-z","article-title":"Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate","volume":"22","author":"Kendler","year":"2011","journal-title":"Osteoporosis international: J established as result cooperation between Eur Foundation Osteoporosis Natl Osteoporosis Foundation USA"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [Rhpth(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.81","article-title":"Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate","volume":"25","author":"Seeman","year":"2010","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on bmd and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2008.04.001","article-title":"Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate","volume":"11","author":"Beck","year":"2008","journal-title":"J Clin densitometry: Off J Int Soc Clin Densitometry"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01768.x","article-title":"Head-to-head comparison of risedronate vs. Teriparatide on bone turnover markers in women with postmenopausal osteoporosis: A randomised trial","volume":"62","author":"Anastasilakis","year":"2008","journal-title":"Int J Clin Pract"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (Amg 162) in a randomized phase 2 study of postmenopausal women with low bmd","volume":"22","author":"Lewiecki","year":"2007","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.061011","article-title":"Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of qct scans in women with osteoporosis","volume":"22","author":"Keaveny","year":"2007","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Internal Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [Recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2019028","article-title":"Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: A systematic review","volume":"60","author":"Chandran","year":"2019","journal-title":"Singapore Med J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.03.008","article-title":"Risk of atrial fibrillation with use of oral and intravenous bisphosphonates","volume":"113","author":"Sharma","year":"2014","journal-title":"Am J Cardiol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.12816\/0033797","article-title":"Benefits and potential risks of bisphosphonate therapy A narrative review","volume":"64","author":"El Osta","year":"2016","journal-title":"Le J Med libanais"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1431676\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T04:39:11Z","timestamp":1725251951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1431676\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":54,"alternative-id":["10.3389\/fendo.2024.1431676"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1431676","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"article-number":"1431676"}}